On LawNext Podcast: In the Wake of KKR’s Acquisition of CLM Company Agiloft, CEO Eric Laughlin Discusses Its Past and Future

Final month, KKR, a significant world funding agency, introduced that it had entered into an settlement to amass a majority stake in Agiloft, the contract lifecycle administration firm. As a part of the deal, the expansion fairness agency FTV Capital, already an Agiloft investor, is making an extra funding, and one other progress fairness agency, JMI Fairness, is becoming a member of as a brand new investor.

The deal was a feather within the cap for Eric Laughlin, who joined Agiloft as CEO in 2020 after main the Pangea3 enterprise at Thomson Reuters. When Laughlin stepped into that function, Agiloft had been in enterprise for 30 years, and he succeeded a predecessor who had been CEO for practically all that point. He got here aboard simply as the corporate had raised its first-ever exterior funding spherical, tasked with the mission of taking the corporate to its subsequent stage of progress. 

Throughout his tenure, the corporate has earned a status as a number one innovator within the CLM house, together with in its improvement of options based mostly on synthetic intelligence, and it has considerably grown each its workforce and its world buyer base. Laughlin has additionally strengthened his personal status as a frontrunner who believes that worker expertise is as vital as buyer expertise. 

In March 2021, not lengthy after he joined Agiloft, Laughlin was our visitor on this present to speak about his plans for the corporate. On at present’s episode, he returns to debate how Agiloft has grown throughout his four-year tenure and to share his ideas on the contract lifecycle administration panorama, now and into the longer term. 

Thank You To Our Sponsors

This episode of LawNext is generously made attainable by our sponsors. We admire their help and hope you’ll test them out.

Should you take pleasure in listening to LawNext, please depart us a evaluation wherever you take heed to podcasts.